Logo image of NANO.PA

NANOBIOTIX (NANO.PA) Stock Fundamental Analysis

EPA:NANO - FR0011341205 - Common Stock

8.59 EUR
+0.3 (+3.62%)
Last: 8/22/2025, 11:22:59 AM
Fundamental Rating

1

Overall NANO gets a fundamental rating of 1 out of 10. We evaluated NANO against 69 industry peers in the Biotechnology industry. Both the profitability and financial health of NANO have multiple concerns. NANO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year NANO has reported negative net income.
In the past year NANO has reported a negative cash flow from operations.
NANO had negative earnings in each of the past 5 years.
NANO had a negative operating cash flow in each of the past 5 years.
NANO.PA Yearly Net Income VS EBIT VS OCF VS FCFNANO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -101.06%, NANO is doing worse than 73.91% of the companies in the same industry.
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NANO.PA Yearly ROA, ROE, ROICNANO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NANO.PA Yearly Profit, Operating, Gross MarginsNANO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

1

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for NANO has been increased compared to 1 year ago.
Compared to 5 years ago, NANO has more shares outstanding
NANO has a worse debt/assets ratio than last year.
NANO.PA Yearly Shares OutstandingNANO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NANO.PA Yearly Total Debt VS Total AssetsNANO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -9.60, we must say that NANO is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -9.60, NANO is not doing good in the industry: 72.46% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -9.6
ROIC/WACCN/A
WACC7.18%
NANO.PA Yearly LT Debt VS Equity VS FCFNANO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 1.04 indicates that NANO should not have too much problems paying its short term obligations.
With a Current ratio value of 1.04, NANO is not doing good in the industry: 72.46% of the companies in the same industry are doing better.
NANO has a Quick Ratio of 1.04. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
NANO has a worse Quick ratio (1.04) than 69.57% of its industry peers.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
NANO.PA Yearly Current Assets VS Current LiabilitesNANO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for NANO have decreased strongly by -33.33% in the last year.
Looking at the last year, NANO shows a very negative growth in Revenue. The Revenue has decreased by -138.62% in the last year.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-150.07%

3.2 Future

Based on estimates for the next years, NANO will show a very strong growth in Earnings Per Share. The EPS will grow by 23.28% on average per year.
The Revenue is expected to grow by 34.65% on average over the next years. This is a very strong growth
EPS Next Y33.28%
EPS Next 2Y27.18%
EPS Next 3Y25.69%
EPS Next 5Y23.28%
Revenue Next Year5.81%
Revenue Next 2Y35.95%
Revenue Next 3Y51.01%
Revenue Next 5Y34.65%

3.3 Evolution

NANO.PA Yearly Revenue VS EstimatesNANO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M 500M
NANO.PA Yearly EPS VS EstimatesNANO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NANO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NANO.PA Price Earnings VS Forward Price EarningsNANO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NANO.PA Per share dataNANO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

NANO's earnings are expected to grow with 25.69% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y27.18%
EPS Next 3Y25.69%

More info and screens

0

5. Dividend

5.1 Amount

NANO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX

EPA:NANO (8/22/2025, 11:22:59 AM)

8.59

+0.3 (+3.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-21 2025-05-21
Earnings (Next)09-16 2025-09-16
Inst Owners27.55%
Inst Owner ChangeN/A
Ins Owners0.64%
Ins Owner ChangeN/A
Market Cap407.21M
Analysts86.67
Price Target11.41 (32.83%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)9.45%
Revenue NY rev (3m)9.45%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.96
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS-0.24
BVpS-1.39
TBVpS-1.39
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.31%
Cap/Sales -7.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -9.6
F-Score2
WACC7.18%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next Y33.28%
EPS Next 2Y27.18%
EPS Next 3Y25.69%
EPS Next 5Y23.28%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-150.07%
Revenue Next Year5.81%
Revenue Next 2Y35.95%
Revenue Next 3Y51.01%
Revenue Next 5Y34.65%
EBIT growth 1Y-155.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year4.84%
EBIT Next 3Y32.21%
EBIT Next 5Y36.1%
FCF growth 1Y-59.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.71%
OCF growth 3YN/A
OCF growth 5YN/A